Background: In the management of Asian patients with acute coronary syndrome (ACS), the comparative cost-effectiveness of ticagrelor and prasugrel, referenced to generic clopidogrel, is unknown. Objective: To assess the cost-effectiveness of ticagrelor and prasugrel as compared with generic clopidogrel in patients with ACS in Singapore. Methods: A Markov model simulating a typical cohort of 62-year-old patients with ACS was constructed from a patient's perspective over a lifetime horizon. Treatment effects and adverse events, including nonfatal myocardial infarction, major bleeding related to non-coronary artery bypass grafting, dyspnea, or death, were estimated from pivotal trials comparing clopidogrel with ticagrelor and prasugrel, respectively. Costs were estimated from a tertiary hospital with more than 1500 admissions for ACS per year. Results: The incremental cost-effectiveness ratio (ICER) per life-year gained for ticagrelor was about three times more favorable than for prasugrel (Singapore dollar [SGD] 13,276 vs. SGD 38,809). The ICER per quality-adjusted life-year (QALY) for prasugrel and ticagrelor, however, was comparable at SGD 18,921 and SGD 18,647, respectively. Deterministic sensitivity analysis revealed that the ICER per QALY gained for prasugrel and ticagrelor was most sensitive to the hazard ratio of all-cause mortality and utility for dyspnea, respectively. Probabilistic sensitivity analysis demonstrated that compared with clopidogrel, the probabilities of prasugrel and ticagrelor being cost-effective are 87.1% and 88.3% based on the willingness-to-pay value of SGD 65,000 (one time the gross domestic product per capita in Singapore). Conclusions: Ticagrelor is more cost-effective than prasugrel in reducing all-cause mortality in patients with ACS. The cost-effectiveness of ticagrelor and prasugrel become similar, however, when accounting for the impact of dyspnea on QALY.
Introduction
Cardiovascular disease, including acute coronary syndrome (ACS), is a leading cause of morbidity and mortality worldwide [1, 2] . Antiplatelet drugs are used to reduce cardiovascular events and premature deaths in these patients. Platelet P2Y 12 receptor antagonists, primarily clopidogrel, added to aspirin therapy is the standard of care for the medical management of ACS [3] .
Notwithstanding clopidogrel's place as standard therapy in ACS, there have been concerns regarding its delayed onset of action, variability in antiplatelet effects [4, 5] , and prolonged recovery of platelet function after discontinuation [6] . Two newer P2Y 12 antagonists have been approved for the management of patients with ACS-prasugrel and ticagrelor. Similar to clopidogrel, prasugrel is an irreversible P2Y 12 receptor antagonist and a prodrug that requires activation but is able to achieve a faster onset of action as compared with clopidogrel. Ticagrelor is a nonthienopyridine antiplatelet agent and is the first reversible oral antagonist of the platelet adenosine diphosphate receptor P2Y 12 . Unlike clopidogrel and prasugrel, ticagrelor is not a prodrug and acts directly on the P2Y 12 receptors. This circumvents the need for metabolic activation as well as any potential influences from genetic variations in cytochrome enzymes on its pharmacological activity. The improved pharmacokinetic and pharmacodynamic profile of these newer antiplatelet agents (faster onset, greater potency) [7, 8] allows one to overcome the limitations of currently available P2Y 12 receptor antagonists.
In pivotal trials, both agents conferred better clinical outcomes in patients with ACS than did clopidogrel [9] . The TRial to assess Improvement in Therapeutic outcomes by Optimizing platelet inhibitioN with prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI) 38 has shown that compared with clopidogrel, prasugrel reduced the composite end point of death, myocardial infarction (MI), or stroke in patients with ACS managed invasively [10] . The PLATelet inhibition and patient Outcomes (PLATO) trial demonstrated that compared with clopidogrel, ticagrelor significantly reduced the composite end point of cardiovascular death, MI, or stroke [11] . Both prasugrel and ticagrelor have been adopted by international clinical practice guidelines for the prevention of secondary thrombotic events in patients with ACS [12, 13] . With the availability of generic clopidogrel, however, differences in drug costs between clopidogrel and the newer antiplatelets have become substantial. The issue of cost-effectiveness of these new interventions needs to be addressed especially in the health care context in which the costs of new therapeutic agents are borne by the patients. To our knowledge, this is the first cost-effectiveness analysis incorporating all the three agents conducted from an Asian perspective. Such analysis is crucial in supporting clinical decisions when outcome improvement and cost containment need to be rationalized. Our study therefore sought to assess the cost-effectiveness of ticagrelor and prasugrel as compared with generic clopidogrel in patients with ACS in Singapore.
Methods

Model Cohort
We developed our model from a cohort of patients with ACS with a median age of 62 years seen at National University Hospital, which is a government-funded tertiary hospital with a case mix of more than 1500 admissions for ACS each year. Patients received prasugrel, ticagrelor, or generic clopidogrel in combination with aspirin.
Model Structure
A Markov model simulating patients over a lifetime horizon was constructed using TreeAge Pro Suite software 2013 (Williamstown, MA). Patients began in the no-event state and transited in yearly cycles through the following events: nonfatal MI, major bleeding related to non-coronary artery bypass graft, dyspnea, and death due to any causes (Fig. 1) . Each state was associated with specific cost and benefit. All patients received antiplatelet treatment during the first 12 months. The model assumed the rates of all events to be equal among the treatment options beyond 12 months. The model tracked the patients until death or when they reached the age of 85 years, with the average life expectancy of the local population being 65 years. The model adopted the patient's perspective. Costs and health outcomes were discounted at 3% annually.
State-Specific Costs
Health care resources and costs were estimated on the basis of information captured by hospital administrative databases ( Table 1) . Estimates of direct medical costs associated with each therapy were derived from the patient's perspective. These included cost for drug treatment, hospital charges and doctor fees for managing ACS and therapeutic complications, and cost for subsequent outpatient care in ACS management. All costs are expressed in local currency, Singapore dollar (SGD), and converted to US dollar (US $) using the November 25, 2013, conversion rate (1 SGD ¼ US $ 0.79) [14] .
State-Specific Health Outcomes
The main outcome of interest was reported in terms of life-year (LY) gained. Quality-adjusted life-years (QALYs) gained that incorporated both the quality and the quantity of life lived were also evaluated to account for the decrement in quality of life imposed by ACS-associated treatment failure and adverse events. Health utility scores were obtained from published literature [15, 16] .
Transition Probabilities
The rate of progression from no-event state to subsequent states, that is, nonfatal MI, major bleeding related to non-coronary artery bypass graft, dyspnea, and death due to any cause(s), were estimated from TRITON-TIMI 38 [10] and PLATO [11] , the pivotal trials comparing clopidogrel with prasugrel and ticagrelor, respectively (Table 2) . Briefly, TRITON-TIMI 38 was a multicenter randomized controlled trial of 13,608 patients with ACS undergoing scheduled percutaneous coronary intervention that compared prasugrel (60 mg loading dose and 10 mg daily maintenance dose) with clopidogrel (300 mg loading dose and 75 mg daily maintenance dose) over 6 to 15 months. Likewise, the PLATO trial was a multicenter randomized controlled trial of 18,624 patients with ACS that compared ticagrelor (180 mg loading dose and 90 mg twice daily maintenance dose) with clopidogrel (300-600 mg loading dose and 75 mg daily maintenance dose) over 12 months. The reported rate of progression was subsequently converted to transition probabilities [17] .
Sensitivity Analyses
Sensitivity analyses were performed on key model parameters to assess the robustness of our findings. A series of one-way sensitivity analyses were performed on all the variables included in Tables 1 and 2 across a priori determined plausible ranges. Because of the large number of input variables included, only the top 10 variables having a relatively larger impact were reported.
Probabilistic sensitivity analyses in which all variables were randomly and simultaneously varied across their plausible ranges were also performed. For each variable in probabilistic sensitivity analyses, their plausible ranges were modeled using a triangle distribution given that the true nature of variance for these variables is not well understood and the triangle distribution does not violate the variable requirements (i.e., costs are >$0, and probabilities and utilities range between 0 and 1).
Results
Base-Case Analysis
As compared with clopidogrel, prasugrel and ticagrelor were associated with greater lifetime QALYs gained of 10.26 and 10.28, respectively (vs. 10.21 for clopidogrel). Similarly, prasugrel and ticagrelor produced greater LYs gained of 10.91 and 10.98, respectively (vs. 10.89 for clopidogrel) ( Table 3) .
The costs incurred for managing ACS including medications and outpatient visits, bleeding episodes, and MI tended to be lower in the generic clopidogrel arm: SGD 26,226 (US $20,719). 
Prasugrel and ticagrelor were projected to exert a higher total cost at SGD 27,138 (US$ 21,439) and SGD 27,535 (US$ 21,753) respectively (Table 3) .
Using clopidogrel as a standard comparator, the ICERs per QALY gained for prasugrel and ticagrelor were comparable at SGD 18,921 (US $14,948) and SGD 18,647 (US $14,731), respectively. The ICER per LY gained for ticagrelor (SGD 13,276 or US $10,488) was lower than that for prasugrel (SGD 38,809 or US $30,659). Prasugrel and ticagrelor were cost-effective alternatives when compared with generic clopidogrel based on the willingness-to-pay (WTP) value of SGD 65,000 (US $51,350) (one time the gross domestic product per capita in Singapore in 2013, a common WTP threshold used by the World Health Organization [18, 19] ).
Sensitivity Analyses
One-way sensitivity analyses were conducted for costs, transition probabilities including hazard ratios, and utilities to determine the influential variables with the most impact on the results of the model. A tornado diagram illustrating the parameters in descending order of influence is presented in Fig. 2 . The results revealed that the hazard ratio of mortality and the utility for noevent state have the largest impact on ICER per QALY gained for prasugrel as compared with clopidogrel. For example, prasugrel was found to be cost-effective as compared with clopidogrel when the hazard ratio of mortality ranged from 0.78 to 1.03, and became less likely to be cost-effective when the hazard ratio exceeded 1.03. The ICER per QALY for ticagrelor as compared with clopidogrel was most sensitive to the utility value for dyspnea and the hazard ratio of mortality. For example, ticagrelor was a cost-effective alternative to clopidogrel when the utility for dyspnea ranged from 0.78 to 1.00, and became less likely to be cost-effective when utility scores fell below 0.78. Changes in other variables have minimal impact on the overall ICER.
Probabilistic sensitivity analysis demonstrated that the probabilities of prasugrel and ticagrelor being cost-effective are 87.1% CABG, coronary artery bypass graft; MI, myocardial infarction. * The range was assumed to be Ϯ25%.
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and 88.3% based on a WTP value of SGD 65,000 (US $51,350) (Fig. 3) . The cost-effectiveness acceptability curve showed that the probability of prasugrel and ticagrelor being cost-effective increased with WTP threshold values. For example, at a threshold value of SGD 30,000 (US $23,700), the probability of prasugrel and ticagrelor for being cost-effective was 77.1% and 64.6%, respectively. When the threshold value is doubled to SGD 60,000 (US $47,400), the probability of prasugrel and ticagrelor for being costeffective became 86.9% and 88.3%, respectively.
Discussion
In this study, we found that prasugrel and ticagrelor were costeffective when compared with generic clopidogrel. Although ticagrelor was comparable to prasugrel in terms of ICER per QALY, it offered a lower ICER per LY gained. Prasugrel and ticagrelor are more potent antiplatelet agents conferring the benefits of improved survival and reduced risk of MI and stent thrombosis as compared with clopidogrel [10, 11] . It must be recognized, however, that an enhancement in antiplatelet potency may be associated with a higher risk of bleeding complications. Furthermore, unique to ticagrelor and resulting from adenosine-mediated adverse effects, dyspnea was reported to occur more frequently with ticagrelor than with clopidogrel (13.8% vs. 7.8%; P o 0.001) [11] . The current model factored these issues into the analysis and estimated the costeffectiveness in terms of both ICER per QALY and LY gained.
Our findings showed a lower ICER per LY gained with ticagrelor relative to prasugrel (SGD 13,276 [US $10,488] vs. SGD 38,809 [US $30,659]). This could be attributed to a relatively greater risk reduction in all-cause mortality associated with ticagrelor relative to prasugrel (hazard ratio 0.95 and 0.78, respectively) [10, 11] . Given that ticagrelor-induced dyspnea offset the LY gained, the QALY and ICER per QALY gained was comparable for both interventions (SGD 18,921 [US $14,948] vs. SGD 18,647 [US $14,731]).
Similar to another study published in the United States, prasugrel yielded larger a ICER per LY relative to ticagrelor because of its greater bleeding rate as compared with ticagrelor [20] . In another cost-effectiveness analysis of ticagrelor performed by the manufacturer with local cost data, ticagrelor was [21] . The relatively lower ICER in this study as compared with our present findings may be partly attributable to the fact that dyspnea-related utility decrement associated with ticagrelor was not factored into the model. Prasugrel and ticagrelor were only recently approved and are costly drug therapies that would result in a significant economic burden, especially on patients receiving these therapies when they are yet to be subsidized by the government. Therefore, the cost-effectiveness analysis was performed from the patient's perspective. There is no local predefined WTP threshold value to interpret the ICER; hence, one time the gross domestic product per capita in Singapore (a common WTP threshold used by the World Health Organization [19] ) was chosen. Because this criterion may not be uniformly accepted or necessarily appropriate for specific decision-making contexts, a cost-effectiveness acceptability curve was also constructed to provide the probability of cost-effectiveness across a range of WTP thresholds.
Deterministic sensitivity analysis revealed that the ICER per QALY gained, for prasugrel and ticagrelor when compared with clopidogrel, was most sensitive to the hazard ratio of all-cause mortality and utility for dyspnea, respectively. Prasugrel became less likely to be cost-effective as compared with clopidogrel when the hazard ratio of all-cause mortality exceeded 1.03. Likewise, ticagrelor became less likely to be cost-effective as compared with clopidogrel when the utility for dyspnea fell below 0.78.
To our knowledge, there has been no analysis comparing the cost-effectiveness of prasugrel and ticagrelor, using clopidogrel as the base case, over a lifetime horizon published in the Asian context. Our analysis can help support clinical decisions on the best "value for money" interventions and maximize health outcomes on the basis of available resources in this region.
Nevertheless, some limitations of our work deserve to be mentioned. First, the analysis was based on the efficacy of antiplatelet treatments in clinical trials. These studies are protocol-driven. Because of the restrictions imposed by the trial protocol in terms of patients' inclusion and medication standardization, the generalizability of the results may be limited. Determining the long-term effectiveness of these treatments posed another challenge given that the drugs were used for only 12 months in these trials. Long-term cost-effectiveness may be better estimated should there be studies evaluating clinical efficacy beyond 12 months. Second, we extracted the efficacy data from different sources (i.e., TRITON-TIMI 38 and PLATO) because of lack of head-to-head data comparing prasugrel and ticagrelor. Differences among trial designs and patient populations pose challenges with cross-trial comparisons. In addition, utility scores were obtained from studies published in the Western context. There may be discrepancies in disutility due to different perception of health across cultural groups. Hence, a local study that estimates utility scores of patients with ACS is warranted. Last, it was assumed that no medical intervention was needed for the management of dyspnea; hence, no direct cost was involved. This may give rise, however, to an underestimation of the total cost.
Conclusions
We determined the costs and benefits associated with two newer P2Y 12 antagonists-prasugrel and ticagrelor-as compared with generic clopidogrel. Both ticagrelor and prasugrel were costeffective compared with clopidogrel. Ticagrelor offered a better ICER per LY gained than did prasugrel. The impact of druginduced dyspnea on QALY, however, offset the cost-effectiveness advantage of ticagrelor over prasugrel. Our results support the need for patient-level cost-effectiveness studies to better understand the impact of drug-induced dyspnea of QALY. Prasugrel Ticagrelor Fig. 3 -Cost-effectiveness Acceptability Curve. The probability of ticagrelor and prasugrel being cost-effective as compared to generic clopidogrel was 77.1% and 64.6% respectively, based on a threshold value of SGD 30,000. At a threshold value of SGD 60,000, the probability for prasugrel and ticagrelor became 86.9% and 88.3% respectively.
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